Predictors of Venous Thromboembolic Events Associated with Central Venous Port Insertion in Cancer Patients
Table 1
Clinical characteristics of the cohort including 1097 consecutive patients receiving their first implantable central venous catheter (catheter port) for antitumoral chemotherapy. values are for patients with VTE () versus patients without event ().
Clinical characteristics
All patients ()
Patients without VTE ()
Patients with any VTE ()
Patients with catheter-related VTE ()
value
Age (median, range)
62 (18 to 89)
63 (18 to 89)
62 (29 to 84)
63 (31 to 84)
NS
Age > 70 y
299 (27.3%)
261 (28%)
38 (23.2%)
26 (21.5%)
NS
Male
617 (56.2%)
527 (56.5%)
90 (54.9%)
65 (53.3%)
NS
BMI (median, range)
25.0 (14.9 to 57.8)
24.4 (14.9 to 51.4)
24.3 (16.1 to 38.1)
24.2 (16.1 to 38.1)
NS
BMI > 35
51 (4.6%)
41 (4.4%)
11 (6.7%)
10 (8.3%)
0.05
Major comorbidities
Coronary heart disease
117 (10.7%)
108 (11.6%)
9 (5.4%)
7 (5.8%)
0.06
Diabetes
138 (12.6%)
122 (13.1%)
16 (9.8%)
15 (12.3%)
NS
Respiratory failure
306 (27.9%)
252 (27%)
54 (32.9%)
48 (39.7%)
0.002
Renal failure
63 (5.7%)
58 (6.2%)
5 (3%)
3 (2.5%)
NS
Previous VTE
118 (10.8%)
99 (10.6%)
19 (11.6%)
16 (13.2%)
NS
Cancer
Lung
260 (23.7%)
207 (22.2%)
53 (32.3%)
47 (38.5%)
<0.001
Colorectal
206 (18.8%)
176 (18.9%)
30 (18.3%)
17 (13.9%)
0.09
Oesogastic
146 (13.3%)
128 (13.8%)
18 (11%)
14 (11.5%)
NS
Breast
120 (10.9%)
106 (11.3%)
14 (8.5%)
10 (8.2%)
NS
ORL
84 (7.7%)
76 (8.1%)
8 (4.9%)
7 (5.7%)
NS
Hepatocholangiopancreas
76 (6.9%)
64 (6.9%)
12 (7.3%)
5 (4.1%)
NS
Lymphomas
75 (6.8%)
69 (7.4%)
6 (3.7%)
5 (4.1%)
NS
Other
130 (11.8%)
107 (11.5%)
23 (14%)
17 (13.9%)
NS
Stage IV
396 (36.1%)
327 (35%)
69 (42.1%)
49 (40.2%)
NS
Performance status 2–4
629 (57.3%)
527 (56.5%)
111 (67.6%)
83 (67.7%)
0.01
CVP placed on left side
86 (7.8%)
64 (6.9%)
21 (12.8%)
17 (14.1%)
0.01
Surgery during 30 days before CVC placement
146 (13.3%)
125 (13.4%)
22 (13.3%)
15 (12.4%)
NS
Major surgery during follow-up
217 (19.8%)
180 (19.3%)
37 (22.6%)
27 (22.3%)
NS
Therapeutic antithrombotic treatment at time of CVP placement
